The FDA accepted a supplemental application for selinexor plus ruxolitinib in myelofibrosis, setting a June 28, 2027, target action date based on phase 3 SENTRY findings.
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.